Compare Orchid Pharma with Jubilant Pharmova - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ORCHID PHARMA vs JUBILANT PHARMOVA - Comparison Results

ORCHID PHARMA     Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ORCHID PHARMA JUBILANT PHARMOVA ORCHID PHARMA/
JUBILANT PHARMOVA
 
P/E (TTM) x -129.0 14.8 - View Chart
P/BV x 37.0 2.8 1,336.5% View Chart
Dividend Yield % 0.0 0.5 -  

Financials

 ORCHID PHARMA   JUBILANT PHARMOVA
EQUITY SHARE DATA
    ORCHID PHARMA
Sep-13
JUBILANT PHARMOVA
Mar-19
ORCHID PHARMA/
JUBILANT PHARMOVA
5-Yr Chart
Click to enlarge
High Rs194898 21.6%   
Low Rs35618 5.7%   
Sales per share (Unadj.) Rs276.5572.0 48.3%  
Earnings per share (Unadj.) Rs-79.236.2 -218.7%  
Cash flow per share (Unadj.) Rs-43.559.5 -73.0%  
Dividends per share (Unadj.) Rs04.50 0.0%  
Dividend yield (eoy) %00.6 0.0%  
Book value per share (Unadj.) Rs53.9301.9 17.9%  
Shares outstanding (eoy) m70.45159.28 44.2%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x0.41.3 31.3%   
Avg P/E ratio x-1.420.9 -6.9%  
P/CF ratio (eoy) x-2.612.7 -20.7%  
Price / Book Value ratio x2.12.5 84.6%  
Dividend payout %012.4 0.0%   
Avg Mkt Cap Rs m8,067120,694 6.7%   
No. of employees `0002.82.4 117.2%   
Total wages/salary Rs m2,52719,260 13.1%   
Avg. sales/employee Rs Th6,956.138,120.6 18.2%   
Avg. wages/employee Rs Th902.58,058.4 11.2%   
Avg. net profit/employee Rs Th-1,993.02,414.3 -82.5%   
INCOME DATA
Net Sales Rs m19,47791,108 21.4%  
Other income Rs m407357 113.9%   
Total revenues Rs m19,88491,466 21.7%   
Gross profit Rs m1,10317,390 6.3%  
Depreciation Rs m2,5193,709 67.9%   
Interest Rs m5,2272,198 237.8%   
Profit before tax Rs m-6,23611,840 -52.7%   
Minority Interest Rs m200-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m511-2,802 -18.2%   
Tax Rs m-1253,268 -3.8%   
Profit after tax Rs m-5,5805,770 -96.7%  
Gross profit margin %5.719.1 29.7%  
Effective tax rate %2.027.6 7.3%   
Net profit margin %-28.76.3 -452.4%  
BALANCE SHEET DATA
Current assets Rs m11,01445,848 24.0%   
Current liabilities Rs m32,06020,897 153.4%   
Net working cap to sales %-108.127.4 -394.6%  
Current ratio x0.32.2 15.7%  
Inventory Days Days9557 167.1%  
Debtors Days Days3451 65.9%  
Net fixed assets Rs m29,44065,498 44.9%   
Share capital Rs m705159 442.2%   
"Free" reserves Rs m2,04347,930 4.3%   
Net worth Rs m3,80048,089 7.9%   
Long term debt Rs m9,01842,429 21.3%   
Total assets Rs m46,510114,685 40.6%  
Interest coverage x-0.26.4 -3.0%   
Debt to equity ratio x2.40.9 269.0%  
Sales to assets ratio x0.40.8 52.7%   
Return on assets %-0.86.9 -10.9%  
Return on equity %-146.912.0 -1,223.9%  
Return on capital %-3.712.4 -30.1%  
Exports to sales %37.90-   
Imports to sales %22.60-   
Exports (fob) Rs m7,378NA-   
Imports (cif) Rs m4,406NA-   
Fx inflow Rs m7,51312,422 60.5%   
Fx outflow Rs m5,64917,227 32.8%   
Net fx Rs m1,865-4,805 -38.8%   
CASH FLOW
From Operations Rs m1,68211,215 15.0%  
From Investments Rs m-9,860-10,118 97.5%  
From Financial Activity Rs m6,6446,574 101.1%  
Net Cashflow Rs m-1,5357,612 -20.2%  

Share Holding

Indian Promoters % 32.3 45.6 70.8%  
Foreign collaborators % 0.0 3.5 -  
Indian inst/Mut Fund % 4.6 8.7 52.9%  
FIIs % 3.3 21.2 15.6%  
ADR/GDR % 4.6 0.0 -  
Free float % 55.3 21.1 262.1%  
Shareholders   84,811 23,815 356.1%  
Pledged promoter(s) holding % 54.9 15.9 346.5%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ORCHID PHARMA With:   ALKEM LABORATORIES  FRESENIUS KABI ONCO.  FDC  ABBOTT INDIA  STRIDES PHARMA SCIENCE  

Compare ORCHID PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 257 Points Higher; Tata Steel & Hindalco Among Top Nifty Gainers(Closing)

Indian share markets witnessed positive trading activity throughout the day today and ended higher.

Related Views on News

JUBILANT LIFE SCIENCES Announces Quarterly Results (4QFY20); Net Profit Up 358.8% (Quarterly Result Update)

Jun 1, 2020 | Updated on Jun 1, 2020

For the quarter ended March 2020, JUBILANT LIFE SCIENCES has posted a net profit of Rs 3 bn (up 358.8% YoY). Sales on the other hand came in at Rs 24 bn (up 0.2% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (3QFY20); Net Profit Down 24.0% (Quarterly Result Update)

Feb 1, 2020 | Updated on Feb 1, 2020

For the quarter ended December 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (down 24.0% YoY). Sales on the other hand came in at Rs 23 bn (down 2.6% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (2QFY20); Net Profit Up 18.9% (Quarterly Result Update)

Oct 31, 2019 | Updated on Oct 31, 2019

For the quarter ended September 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (up 18.9% YoY). Sales on the other hand came in at Rs 23 bn (down 0.2% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

JUBILANT LIFE SCIENCES 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of JUBILANT LIFE SCIENCES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of JUBILANT LIFE SCIENCES. Also includes updates on the valuation of JUBILANT LIFE SCIENCES.

JUBILANT LIFE SCIENCES Announces Quarterly Results (1QFY20); Net Profit Down 7.7% (Quarterly Result Update)

Jul 29, 2019 | Updated on Jul 29, 2019

For the quarter ended June 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (down 7.7% YoY). Sales on the other hand came in at Rs 22 bn (up 5.0% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

More Views on News

Most Popular

Time to Buy Smallcaps?(Fast Profits Daily)

Apr 30, 2021

In this video, I'll show you why I favour smallcaps over the Nifty.

The Next Smallcap Winners(Profit Hunter)

Apr 30, 2021

Price is the only due diligence one might require to buy this business.

Sell in May and Go Away?(Fast Profits Daily)

Apr 28, 2021

Does the concept of selling stocks in the month of May, work in the Indian market?

This Fund Manager Has Taken the World by Storm. Will You Invest With Her?(Profit Hunter)

Apr 26, 2021

Should you invest with this Rockstar fund manager who has outperformed in a big way?

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ORCHID PHARMA SHARE PRICE


May 7, 2021 (Close)

TRACK ORCHID PHARMA

  • Track your investment in ORCHID PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ORCHID PHARMA 8-QTR ANALYSIS

COMPARE ORCHID PHARMA WITH

MARKET STATS